Corpore Sano a company innovating to solve the problems of your heart.

2. Global Burden of Cardiovascular
Disease
Accounts for 17.5 million deaths
annually.
Number 1 killer globally.

3. 45 people have died in 1.5
minutes
In 90% of all cases,
Cardiovascular Disease is
preventable with early detection.
*American Heart Association

4. CORPORE SANO:
TRIPLE THREAT
CHECK
“YOUR HEART AT THE TIP OF YOUR FINGER”
By: Gitika Kumar, Shikha Lakhani, Yera Patel,
Arnav Ramu

5. Organization Structure

7. Moving the Needle
Heart
Attack, ICU
Admission, Loss of
Productivity.
Screening for Risk
Factors
Lipid Panel & Glucose
.
DEATH
or
REHAB
.
Healthy
Lifestyle
.
Developin
g
Countries

8. Biomarkers for Cardiovascular
Disease
 Lipid Panel
 Contains LDL (“Bad Cholesterol”)
 Glucose
 Diabetics 2 to 4 times higher risk for developing CVD
 High Sensitive C-Reactive Protein (HS-CRP)
 Indicator for inflammation
 New indicator for Cardiovascular Disease

9. JUPITER Trial
 Conducted by Dr. Ridker at Brigham and
Women's Hospital
 Found that HS-CRP is an earlier indicator
for CVD than LDL
 Trial was sponsored by AstraZeneca

10. The Product- Triple Threat Check
(3TC)

11. Why use 3TC?
Device Name Triple Threat
Check
CardioChek
Plus
Alere
Cholestech
LDX
Walk in Clinic
Testing
Lipid Panel
Glucose
High Sensitive
C-Reactive
Protein
Portable
Accuracy
Results Within
5 Minutes
Price $750 $980 $2600 $90 - $120 (Per
Individual)

12. Benefits
Rapid Results
Ease of Use
Cost Effective
Portable
Minimally Invasive

13. “ A device like this would revolutionize medical care
in third world countries we could save countless lives
when we visit villages where the nearest hospital is
hours away ”
Dr. Jason Moore – Emergency Physician, DMC

14. Potential Market
 Total Potential Market: 500,000 Customers
 Primary Care Providers
 Clinics/ Hospitals
 Non-Governmental Organizations (NGOs)
 Retail Pharmacies
 Potential Patients: Entire Population

15. Go-To-Market Strategy

16. Marketing and Sales Strategy
Triple Threat Check
Marketing
Strategy
Online
Marketing
Endorsements
through Leaders
Medical
Journals/ Case
Studies
Conferences
and Trade
Shows
Sales Strategy
* Consists of
Sales Force
Retail
Pharmacies
Healthcare GPOs Online

17. Operations & Manufacturing
Assembly by Contract
Manufacturers
Quality Testing and Validation
Packaging and Shipping
Distribution
Channels

18. Product Rollout

19. Pricing Strategy
COGS of 3TC: $150
Price of 3TC: $750
COGS of Set of 3 Test Strips: $0.75
Price of Set of 3 Test strips: $7.50

20. Financial Discussion: Operational
Highlights
The following assumptions are as follows:
Total Market Potential: 500,000
0.15
0.45
1.35 4.05
12.15
87.85
Available Market
Year 2
Year 3
Year 4
Year 5
Year 6
Competitors' Market Share
Operational Highlights
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Market Capture 0.00% 0.15% 0.45% 1.35% 4.05% 12.15%
Number of Customers 0 250 750 2,250 6,750 20,250
Number of Devices Sold 0 750 2,250 6,750 20,250 60,750
Revenue from Devices $0.00 $562,500 $1,687,500 $5,062,500 $15,187,500 $45,562,500
Number of Test Strips 0 93,750 337,500 1,350,000 5,062,500 18,225,000
Revenue from Strips $0.00 $703,125 $2,531,250 $10,125,000 $37,968,750 $136,687,500
Total Revenue $0.00 $1,265,625 $4,218,750 $15,187,500 $53,156,250 $182,250,000
Number of Employees 3 5 12 40 60 80

21. Financial Discussion: Financial
Highlights
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Total Revenue $0.00 $1,265,625 $4,218,750 $15,187,500 $53,156,250 $182,250,00
0
Interest on the Loan at
15%
$0.00 $0.00 $681,000 $681,000 $681,000 $5,523,000
Total Expenses $2,860,000 $1,672,656 $4,204,438 $10,584,125 $23,688,813 $62,994,750
EBITDA -$2,860,000 -$407,031 $695,313 $5,284,375 $30,148,438 $124,476,25
0
EBITDA % n/a -32.2% 16.5% 34.8% 56.7% 68.3%
Gross Profit -$2,860,000 -$407,031 $14,313 $4,603,375 $29,467,438 $119,255,250

22. Startup Expenses
Design/ Testing/ Validation
FDA Approval/ Proof of Concept
Product Awareness/Pre-Launch Program
Design/ Product Patent Filing
Product Design Engineer
Website Development
Programmers
Biochemist
Patent Attorney/ IP Lawyer
R & D
Royalty Payment
General Admin Expenses
Other Start Up Expenses
Manufacturing Costs
Payroll
$1,000,000
$200,000
$100,000
$25,000
$80,000
$5,000
$80,000
$80,000
$100,000
$450,000
$750,000
$163,000
$100,000
$780,000
$610,000
Total Preliminary Expenses $4,523,000

23. Future Plans- After Year 6
 Reduce cost of Triple Threat Check
 New Features- Data Collection, Data Analysis
 Provide prescribed lifestyle plans to patients.
 Expand to newly diagnosed diabetics - HbA1C
 We plan to further diversify our product offering after
year 6.

24. Risk Mitigation Strategy
Experienced board of Advisors
Protected Intellectual
Property
Serve the needs of the
Market
Device Safety

25. Why Invest?
Solving a global problem profitably
Next big innovation in preventative
medicine
 Significant Return on investment
Ambitious and Hard-Working
450 More People Died
During 15 Minutes
* Taken From World Health Organization